BackShanghai Junshi Biosciences , Ltd. Overview

Shanghai Junshi Biosciences , Ltd. Current Assets

Track Shanghai Junshi Biosciences , Ltd.'s current assets ($5.2B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$5.21B
↑ 8.79% YoYΔ $420.49M vs prior year quarter

Peer trimmed avg / median

Loading

Shanghai Junshi Biosciences , Ltd. Current Assets History

Loading

Shanghai Junshi Biosciences , Ltd. vs. peers: Current Assets Comparison

Loading

Shanghai Junshi Biosciences , Ltd. Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Shanghai Junshi Biosciences , Ltd. (688180.SS) FAQ

As of the most recent data (June 2026), 688180.SS shows a current assets of $5.2B. That compares with $4.8B in the prior-year period — up 8.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 688180.SS's current assets is now $5.2B (was $4.8B) — a 8.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Shanghai Junshi Biosciences , Ltd. is outperforming or lagging.

Tracking 688180.SS's current assets over time shows whether Shanghai Junshi Biosciences , Ltd. is scaling, shrinking, or reshaping that part of the business. The current reading is $5.2B That compares with $4.8B in the prior-year period — up 8.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has Shanghai Junshi Biosciences , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $5.2B) with ownership activity and broader fundamentals.

Shanghai Junshi Biosciences , Ltd.'s current assets is $5.2B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.